{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-037525","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.914018+00:00","generated_at":"2026-05-29T02:56:32.886347+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Genprex completes Phase 1 dose escalation of Reqorsa + Tecentriq in ES-SCLC; Phase 2 opens","bullets":["No dose-limiting toxicities observed; RP2D set at 0.12 mg/kg (highest dose tested).","Safety Review Committee approved opening Phase 2 expansion; enrollment has started.","Phase 2 will enroll ~50 patients at 10-15 U.S. sites; primary endpoint is 18-week PFS rate.","Futility analysis after 25th patient reaches 18 weeks of follow-up.","Acclaim-3 has FDA Fast Track and Orphan Drug designations for ES-SCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-037525","json":"https://secwatch.observer/filing/0001437749-24-037525.json","markdown":"https://secwatch.observer/filing/0001437749-24-037525.md","text":"https://secwatch.observer/filing/0001437749-24-037525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924037525/0001437749-24-037525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924037525/gnpx20241205_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:56:32.886347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}